An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will release its third quarter 2022 financial results on November 9, 2022, before market opening. The Company aims to discuss these results on a conference call at 8:00 a.m. ET. Interested parties can access the call via toll-free number 800-245-3047 or through a live webcast available on their website. A replay will be available shortly after the call. ANI focuses on developing, manufacturing, and marketing branded and generic pharmaceuticals to meet high medical needs.
Positive
None.
Negative
None.
BAUDETTE, Minn.--(BUSINESS WIRE)--
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, prior to market open.
Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-753-6120 and entering access code 1159760.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com
